Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Younger age at onset of colorectal cancer is associated with increased patient's delay

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  1. Plasma IL-8 and ICOSLG as prognostic biomarkers in glioblastoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Perspective: targeting VEGF-A and YKL-40 in glioblastoma - matter matters

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Maria Thomsen
  • Marianne Grønlie Guren
  • Eva Skovlund
  • Bengt Glimelius
  • Marianne Jensen Hjermstad
  • Julia S Johansen
  • Elin Kure
  • Halfdan Sorbye
  • Per Pfeiffer
  • Thoralf Christoffersen
  • Tormod Kyrre Guren
  • Kjell Magne Tveit
Vis graf over relationer

BACKGROUND: The aim of this study was to evaluate the effect of cetuximab on health-related quality of life (HRQoL) in the NORDIC-VII trial on metastatic colorectal cancer (mCRC), and to assess HRQoL in relation to RAS and BRAF mutation status and inflammatory biomarkers.

PATIENT AND METHODS: HRQoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30) at baseline, after every fourth cycle of chemotherapy, and at the end of treatment. HRQoL during 12 cycles of chemotherapy was evaluated over time, compared between treatment arms, and assessed for association with tumour mutation status and inflammatory markers.

RESULTS: QLQ-C30 was completed by 512 patients (90%) before start of treatment. HRQoL variables were well balanced across treatment arms at baseline, and no statistically significant differences during treatment were seen. Patients with BRAF-mutated tumours reported poorer HRQoL at baseline and subsequent time points than patients with RAS-mutated or RAS/BRAF wild-type tumours. Patients with high serum interleukin-6 (IL-6) or C-reactive protein (CRP) had markedly impaired HRQoL compared to patients with normal levels. There was a statistically significant association between reduction in IL-6 and CRP levels and improvement in HRQoL during treatment from baseline to cycle 4.

CONCLUSION: The addition of cetuximab to chemotherapy did not affect HRQoL in mCRC patients. Patients with BRAF-mutated tumours have both a worse prognosis and a poor HRQoL. The associations between levels of systemic inflammatory markers and reduced HRQoL suggest that the patients might benefit from anti-inflammatory treatment.

TidsskriftEuropean journal of cancer (Oxford, England : 1990)
Sider (fra-til)26-35
Antal sider10
StatusUdgivet - aug. 2017

ID: 52654626